European Union - English - EMA (European Medicines Agency)

astrazeneca ab - chadox1-sars-cov-2 - covid-19 virus infection - vaccines - vaxzevria is indicated for active immunisation to prevent covid 19 caused by sars cov 2, in individuals 18 years of age and older.the use of this vaccine should be in accordance with official recommendations.

Australia - English - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - chadox1-s, quantity: 100000000000 vp/ml - injection, solution - excipient ingredients: histidine; magnesium chloride hexahydrate; sucrose; disodium edetate; polysorbate 80; sodium chloride; histidine hydrochloride monohydrate; ethanol absolute; water for injections - vaxzevria has provisional approval for the indication:,active immunisation of individuals greater than or equal to 18 years old for the prevention of coronavirus disease 2019 (covid-19) caused by sars-cov-2.,the use of this vaccine should be in accordance with official recommendations.,the decision has been made on the basis of short term efficacy and safety data. continued approval is dependent upon the evidence of longer-term efficacy and safety from ongoing clinical trials and post-market assessment.

European Union - English - EMA (European Medicines Agency)

sanofi pasteur - sars-cov-2 prefusion spike delta tm protein, recombinant (b.1.351 strain) - covid-19 virus infection - vaccines - vidprevtyn beta is indicated as a booster for active immunisation to prevent covid-19 in adults who have previously received an mrna or adenoviral vector covid-19 vaccine (see sections 4.2 and 5.1 in product information document).the use of this vaccine should be in accordance with official recommendations.

European Union - English - EMA (European Medicines Agency)

hipra human health s.l. - sars-cov-2 virus recombinant spike (s) protein receptor binding domain (rbd) fusion heterodimer – b.1.351-b.1.1.7 strains - covid-19 virus infection - vaccines - bimervax is indicated as a booster for active immunisation to prevent covid-19 in individuals 16 years of age and older who have previously received a mrna covid-19 vaccine

New Zealand - English - Medsafe (Medicines Safety Authority)

astrazeneca limited - chadox1-s 100 gvp/ml (gvp = giga viral particles; equivalent to not less than to 5.0 x 10^8 infectious units per ml);  ;  ;   - solution for injection - active: chadox1-s 100 gvp/ml (gvp = giga viral particles; equivalent to not less than to 5.0 x 10^8 infectious units per ml)       excipient: disodium edetate dihydrate ethanol histidine histidine hydrochloride monohydrate magnesium chloride hexahydrate polysorbate 80 sodium chloride sucrose water for injection - covid-19 vaccine astrazeneca is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 18 years of age and older. the use of this vaccine should be in accordance with official recommendations.

Canada - English - Health Canada

novavax inc. - sars-cov-2 recombinant spike protein (omicron xbb.1.5) - suspension - 5mcg - sars-cov-2 recombinant spike protein (omicron xbb.1.5) 5mcg

European Union - English - EMA (European Medicines Agency)

valneva austria gmbh - covid-19 vaccine (inactivated, adjuvanted, adsorbed) - covid-19 virus infection - vaccines - covid-19 vaccine (inactivated, adjuvanted) valneva is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 18 to 50 years of age. the use of this vaccine should be in accordance with official recommendations.

Canada - English - Health Canada

astrazeneca canada inc - chadox1-s [recombinant] - solution - 50000000000vp - chadox1-s [recombinant] 50000000000vp

Canada - English - Health Canada

astrazeneca canada inc - chadox1-s [recombinant] - solution - 50000000000vp - chadox1-s [recombinant] 50000000000vp

Canada - English - Health Canada

verity pharmaceuticals inc. - chadox1-s [recombinant] - solution - 50000000000vp - chadox1-s [recombinant] 50000000000vp